One key area of focus for the partnership is healthcare and life sciences, where generative AI can significantly aid in computer-aided drug discovery and understanding drug molecules' interaction with biological targets. NVIDIA’s BioNeMo™ FMs will soon be available on AWS HealthOmics, a service designed for healthcare and life sciences organizations. The partnership also emphasizes security, with AWS AI infrastructure and services providing control over data and ensuring it is not shared with third-party model providers. The integration of NVIDIA and AWS technologies in the cloud will further enhance this secure environment.
Key takeaways:
- AWS and NVIDIA announced that the new NVIDIA Blackwell GPU platform is coming to AWS, which will significantly speed up inference workloads for resource-intensive, multi-trillion parameter language models.
- The collaboration between AWS and NVIDIA is expanding computer-aided drug discovery with new AI models to help researchers in healthcare and life sciences.
- The AI supercomputer collaboration between AWS and NVIDIA, Project Ceiba, will use the Blackwell platform and will be capable of processing a massive 414 exaflops of AI, a 6x performance increase over earlier plans.
- AWS AI infrastructure and services have security features in place to protect customer data, and the latest combination and integration of NVIDIA and AWS technologies in the cloud extends that secure environment further.